Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Trastuzumab + SOX in HER2+ Gastric Cancer
NCT06439550Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of serplulimab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06439550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439550.